Loading...
Indian Pharmaceutical Exporter · #1 for Telmisartan · $81.0M export value · DGFT Verified
Cipla Limited is the #1 Indian exporter of Telmisartan with $81.0M in export value and 1,619 verified shipments. Cipla Limited holds a 0.7% market share in Telmisartan exports across 5 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
| 4 |
| 0.1% |
Cipla Limited exports Telmisartan to 5 countries. The largest destination is GERMANY accounting for 96.7% of Cipla Limited's Telmisartan shipments, followed by MAURITIUS (1.7%) and SRI LANKA (1.2%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| B LOGISTIK GMBH | GERMANY | $19.4M | 1,540 |
| BOEHRINGER INGELHEIM INTERNATIONAL | GERMANY | $452.9K | 30 |
| BREATHEFREE LANKA PVT LTD | SRI LANKA | $242.6K | 22 |
| IBL LTD (HEALTHACTIV) | MAURITIUS | $199.1K | 11 |
| IBL LIMITED - HEALTHACTIV | MAURITIUS | $82.3K | 3 |
| JDS CO LTD | MYANMAR | $45.2K | 2 |
| IBL LIMITED HEALTHACTIV | MAURITIUS | $37.0K | 2 |
| CIPLA MALAYSIA SDN BHD | MALAYSIA | $26.8K | 4 |
| JDS CO, LTD | MYANMAR | $12.8K | 1 |
| IBL LIMITED | MAURITIUS | $11.1K | 2 |
Cipla Limited supplies Telmisartan to 11 buyers globally. The largest buyer is B LOGISTIK GMBH (GERMANY), followed by BOEHRINGER INGELHEIM INTERNATIONAL (GERMANY) and BREATHEFREE LANKA PVT LTD (SRI LANKA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
India exported $172.2M worth of Telmisartan through 11,086 shipments from 413 suppliers to 132 countries, serving 1,116 buyers globally. Cipla Limited contributes $81.0M to this total, accounting for 0.7% of India's Telmisartan exports. Cipla Limited ships Telmisartan to 5 countries through 11 buyers.
Cipla Limited's average Telmisartan shipment value is $50.0K per consignment, based on 1,619 shipments totaling $81.0M. The largest destination is GERMANY (96.7% of Cipla Limited's Telmisartan exports).
Cipla Limited ranks #1 among 413 Indian Telmisartan exporters with a 0.7% market share. The top 3 exporters are CIPLA LIMITED ($81.0M), INTAS PHARMACEUTICALS LIMITED ($15.5M), MYLAN LABORATORIES LIMITED ($12.0M). Cipla Limited processed 1,619 shipments to 5 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| TELMISARTAN AND AMLODIPINE TABLETS 40/5M | $3.2M | 228 |
| TELMISARTAN AND AMLODIPINE TABLETS 80/5M | $2.7M | 187 |
| TELMISARTAN AND AMLODIPINE TABLETS 80/10 | $1.7M | 117 |
| TELMISARTAN AND AMLODIPINE TABLETS 40/10 | $379.8K | 27 |
| TELMISARTAN AND AMLODIPINE TABLETS80/10M | $302.3K | 22 |
| TELMISARTAN AND AMLODIPINE TABLETS 40/5MG(NDA)[PAC SIZE:2X20000X23.042 PAC=921680 NOS](TELMISARTAN & AMLODIPINE 40/5MG) | $148.1K | 10 |
| CRESAR - 40 TABLETS TELMISARTAN TABLETS | $80.2K | 3 |
| CRESAR - 40 TABLETS (TELMISARTAN TABLETS | $78.2K | 3 |
| TELMISARTAN AND AMLODIPINE TABLETS 40/5MG(NDA)[PAC SIZE:2X20000X23.393 PAC=935720 NOS](TELMISARTAN & AMLODIPINE 40/5MG) | $73.8K | 5 |
| TELMISARTAN AND AMLODIPINE TABLETS 40/5MG(NDA)[PAC SIZE:2X20000X23.297 PAC=931880 NOS](TELMISARTAN & AMLODIPINE 40/5MG) | $73.5K | 5 |
Cipla Limited exports 680 distinct Telmisartan formulations including tablets, capsules, syrups, and combination drugs. The top formulation is TELMISARTAN AND AMLODIPINE TABLETS 40/5M with 228 shipments worth $3.2M. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
What Cipla Limited must comply with to export Telmisartan to its top destination countries
Approval Process
Marketing Authorisation via Decentralized or Mutual Recognition Procedure under EU Directive 2001/83/EC. CTD Module 1–5 dossier required.
Timeline: 12–18 months via Decentralized Procedure
GMP & Export Requirements
EU GMP (EudraLex Vol. 4); GMP certificate from EU competent authority; WHO Prequalification accepted as supporting evidence
Certificate of Pharmaceutical Product (CPP) from CDSCO; Written Confirmation for API export per EU requirements; EU FMD serialization mandatory
Note: Indian manufacturers must hold EU GMP certificate. EU Falsified Medicines Directive (FMD) serialization and tamper-evident packaging mandatory.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
Exporters ranked immediately above and below #1 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | CIPLA LIMITED ★ | $81.0M | 1,619 | 5 | $50.0K |
| 3 | INTAS PHARMACEUTICALS LIMITED | $15.5M | 461 | 19 | $33.7K |
| 2 | MYLAN LABORATORIES LIMITED | $12.0M | 240 | 4 | $50.0K |
Cipla Limited ranks #1 among 413 Indian Telmisartan exporters. Average shipment value of $50.0K compared to the market average of $416.8K. The closest competitors by value are INTAS PHARMACEUTICALS LIMITED and MYLAN LABORATORIES LIMITED.
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 1,766 | 15.9% |
| SAHAR AIR | 1,729 | 15.6% |
| DELHI AIR CARGO ACC (INDEL4) | 1,003 | 9.0% |
| NHAVA SHEVA SEA (INNSA1) | 755 | 6.8% |
| DELHI AIR | 623 | 5.6% |
| AHEMDABAD AIR | 402 | 3.6% |
| Bombay Air | 396 | 3.6% |
| JNPT | 377 | 3.4% |
Cipla Limited also exports these cardiovascular products. Each links to the detailed product page.
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
Cipla Limited exports 98 products worth $1.1B. Beyond Telmisartan, top products include Fluticasone, Amlodipine, Salbutamol, Salmeterol, Budesonide. View the complete Cipla Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Telmisartan — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Verify manufacturer licensing and export certifications with the official agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 132+ countries, 1,116+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Telmisartan exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Telmisartan. For current shipment-level data, contact TransData Nexus.